M&A Deal Summary

Sarepta Therapeutics Acquires Myonexus Therapeutics

On February 27, 2019, Sarepta Therapeutics acquired life science company Myonexus Therapeutics for 165M USD

Acquisition Highlights
  • This is Sarepta Therapeutics’ 1st transaction in the Life Science sector.
  • This is Sarepta Therapeutics’ largest (disclosed) transaction.
  • This is Sarepta Therapeutics’ 1st transaction in the United States.
  • This is Sarepta Therapeutics’ 1st transaction in Ohio.

M&A Deal Summary
Date 2019-02-27
Target Myonexus Therapeutics
Sector Life Science
Buyer(s) Sarepta Therapeutics
Deal Type Add-on Acquisition
Deal Value 165M USD
Advisor(s) William Blair (Financial)
Thompson Hine
Fenwick & West LLP (Legal)

Target

Myonexus Therapeutics

New Albany, Ohio, United States
website
Myonexus Therapeutics is a clinical stage, rare disease gene therapy company developing first ever treatments for limb girdle muscular dystrophies (LGMDs) based on research at Nationwide Children’s Hospital, a provider in neuromuscular gene therapy discovery and translational research. Myonexus Therapeutics was founded in 2017 and is based in New Albany, Ohio.

Search 192,723 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Sarepta Therapeutics

Cambridge, Massachusetts, United States

website

Category Company
Founded 1980
Sector Life Science
Employees1,162
Revenue 933M USD (2022)
DESCRIPTION

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. Sarepta Therapeutics was founded in 1980 and is based in Cambridge, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Ohio) 1 of 1
Country (United States) 1 of 1
Year (2019) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal